Volume 17, Issue 1 (Winter 2026)
Caspian J Intern Med 2026, 17(1): 74-81 |
Back to browse issues page
Alireza Tavakolizadeh 
, Hamideh Mohammadzadeh * , Ali Mohammad Mokhtari , Younes Karami , Milad Khorasani , Zahra Saadatian , Zahra Rajabzadeh , Mohammad Amin Momeni-Moghaddam
, Hamideh Mohammadzadeh * , Ali Mohammad Mokhtari , Younes Karami , Milad Khorasani , Zahra Saadatian , Zahra Rajabzadeh , Mohammad Amin Momeni-Moghaddam
Department of Dermatology, School of Medicine, Gonabad University of Medical Sciences,Gonabad, Iran , Mohammadzadeh.hamideh@yahoo.com
Abstract: (506 Views)
Background: Acne vulgaris (AV) is a common inflammatory skin disorder. Systemic treatments like azithromycin and doxycycline are frequently used. The Angiotensin-Converting Enzyme (ACE) has been implicated in inflammation and skin diseases. This study investigated the association between ACE I/D polymorphism and therapeutic response to azithromycin versus doxycycline in moderate AV.
Methods: This clinical trial enrolled 54 moderate AV patients divided equally into two groups: one received 100 mg/day doxycycline, the other 250 mg/day azithromycin for 3 months. DNA was extracted via salting-out method, and ACE I/D polymorphism was analyzed by PCR and electrophoresis. Treatment efficacy was assessed using Michelson’s acne score and standardized photography. Post-treatment, genotype-phenotype correlations were evaluated.
Results: The doxycycline group showed significantly higher recovery rates (59.3%) compared to azithromycin (18.5%) (p<0.001). However, no statistically significant association was observed between improvement percentages and genotypes in either the doxycycline ((P = 0.567) or azithromycin (P = 0.533) groups.
Conclusion: Doxycycline was significantly more effective than azithromycin for moderate AV. However, no significant association was found between ACE I/D polymorphism and treatment response for either antibiotic. These findings guide therapeutic selection while suggesting that ACE genotyping may not predict treatment response in moderate AV.
Methods: This clinical trial enrolled 54 moderate AV patients divided equally into two groups: one received 100 mg/day doxycycline, the other 250 mg/day azithromycin for 3 months. DNA was extracted via salting-out method, and ACE I/D polymorphism was analyzed by PCR and electrophoresis. Treatment efficacy was assessed using Michelson’s acne score and standardized photography. Post-treatment, genotype-phenotype correlations were evaluated.
Results: The doxycycline group showed significantly higher recovery rates (59.3%) compared to azithromycin (18.5%) (p<0.001). However, no statistically significant association was observed between improvement percentages and genotypes in either the doxycycline ((P = 0.567) or azithromycin (P = 0.533) groups.
Conclusion: Doxycycline was significantly more effective than azithromycin for moderate AV. However, no significant association was found between ACE I/D polymorphism and treatment response for either antibiotic. These findings guide therapeutic selection while suggesting that ACE genotyping may not predict treatment response in moderate AV.
Policy Brief: Original Article |
Subject:
Dermathology
Received: 2025/07/27 | Accepted: 2025/10/12 | Published: 2026/01/11
Received: 2025/07/27 | Accepted: 2025/10/12 | Published: 2026/01/11
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |